StockIQpro
NASDAQ:TNXP

Tonix Pharmaceuticals Holding Corp.

Track all markets on TradingView
Track all markets on TradingView

Tonix Pharmaceuticals Holding Corp.'s revenue grew 29.8% in fiscal 2025 to $13.1M while operating margin rose to −959.1%, its highest in 3 years. Free cash flow was −$103.2M, −787.5% of revenue, and the diluted share count rose 1055.9%.Summary generated from Tonix Pharmaceuticals Holding Corp.'s SEC filings. Latest annual report filed Mar 12, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$13.1M
Revenue growth+29.8%
Revenue, 5-yr CAGRn/a
Gross margin49.3%
Operating margin−959.1%
Net margin−946.2%
ROICn/a
Return on equity−64.5%
Debt / equityn/a
Free cash flow−$103.2M
FCF margin−787.5%
Share count change+1055.9%

Financials

Fiscal years, $M
Item20212022202320242025
Revenuen/an/a81013
Operating income−92−112−118−137−126
Net income−92−110−117−130−124
Free cash flow−111−146−110−61−103

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations